|
| CASE REPORT |
 |
|
|
| Year : 2017 |
Volume
: 28 | Issue : 1 | Page
: 154-157 |
|
Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient
Omar Dahmani1, Christine Sophoclis2, Malika Kebir2, Djemai Bouguern1, Aboubacry Sakho2, Pascale Demarchi1
1 Department of Nephrology and Dialysis, Hospital Louis Jaillon, Saint-Claude, France
2 Secondary Care, Hospital Louis Jaillon, Saint-Claude, France
Correspondence Address:
Omar Dahmani
Department of Nephrology and Dialysis Hospital Louis Jaillon, Saint-Claude
France
  | Check |
DOI: 10.4103/1319-2442.198239 PMID: 28098117 
|
|
|
The acronym of malignancy, iatrogenic, intoxication and immobilization, sarcoidosis, hyperparathyroidism and hyperthyroidism, milk-alkali syndrome, and paget is very helpful in diagnosing hypercalcemia. We report on a 94-year-old patient with history of end-stage renal failure secondary to benign nephroangiosclerosis, who was on maintenance hemodialysis during dialysis, his blood chemistry revealed mild hypercalcemia (2.66 mmol/L) with normal level of intact primary hyperparathyroidism (32.37 ng/mL) mandating the discontinuation of Vitamin D[3]. In view of persisting hypercalcemia, denosumab 60 mg/mL was administrated subcutaneously. The serum calcium level showed a decrease and stabilized at near upper limit (2.57 mmol/L). Three weeks later, the serum calcium remained mildly elevated fluctuating between 2.66 and 2.80 mmol/L. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
|
|
